The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 351:1306-1313 September 23, 2004 Number 13
NextNext

A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup
Candice L. Bjornson, M.D., Terry P. Klassen, M.D., Janielee Williamson, R.N., Rollin Brant, Ph.D., Craig Mitton, Ph.D., Amy Plint, M.D., Blake Bulloch, M.D., Lisa Evered, M.D., David W. Johnson, M.D., for the Pediatric Emergency Research Canada Network

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set
-Supplementary Material

Commentary
-Perspective
 by Klass, P.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background The benefits of dexamethasone treatment for moderate-to-severe croup are well established. However, most children with croup have mild symptoms, and it is unknown whether they would derive the same degree of benefit from dexamethasone treatment as children with more severe disease.

Methods We conducted a double-blind trial at four pediatric emergency departments in which 720 children with mild croup were randomly assigned to receive one oral dose of either dexamethasone (0.6 mg per kilogram of body weight) or placebo. The children had mild croup, as defined by a score of ≤2 on the croup scoring system of Westley et al. The primary outcome was a return to a medical care provider for croup within seven days after treatment. The secondary outcome was the presence of ongoing symptoms of croup on days 1, 2, and 3 after treatment. Other outcomes included economic costs, hours of sleep lost by the child, and stress on the part of the parent in relation to the child's illness.

Results Baseline clinical characteristics were similar in the two groups. Return to medical care was significantly lower in the dexamethasone group (7.3 percent vs. 15.3 percent, P<0.001). In the dexamethasone group, there was quicker resolution of croup symptoms (P=0.003), less lost sleep (P<0.001), and less stress on the part of the parent (P<0.001).

Conclusions For children with mild croup, dexamethasone is an effective treatment that results in consistent and small but important clinical and economic benefits. Although the long-term effects of this treatment are not known, our data support the use of dexamethasone in most, if not all, children with croup.


Source Information

From the Department of Pediatrics (C.L.B., J.W., D.W.J.), the Department of Community Health Sciences (R.B.), and the Department of Pharmacology and Therapeutics (D.W.J.), University of Calgary, Calgary, Alta.; the Department of Pediatrics, University of Alberta, Edmonton (T.P.K., L.E.); the Center for Healthcare Innovation and Improvement, University of British Columbia, Vancouver (C.M.); the Department of Pediatrics, University of Ottawa, Ottawa, Ont. (A.P.); and the Department of Pediatrics, University of Manitoba, Winnipeg (B.B.) — all in Canada.

Address reprint requests to Dr. Johnson at the Child Health Research Group, Alberta Children's Hospital, 1820 Richmond Rd. SW, Calgary, AB T2T 5C7, Canada.

Full Text of this Article


Related Letters:

Oral Dexamethasone for Mild Croup
Vernacchio L., Mitchell A. A., Marchetti F., Longo G., Ventura A., Singh H., Chugh J. C., Bjornson C., Johnson D. W., Klassen T.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2768-2769, Dec 23, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.